Study design
This prospective, randomized, single-blind controlled study was
conducted with the approval of the institutional review board of our
institute (No. 2-106-05-042) and was officially listed and accepted at
www.ClinicalTrials.gov with the registration number NCT03031041. From
January 2017 to August 2019, 50 individuals diagnosed with
mild-to-moderate CTS were eligible, and 47 were enrolled in this study.
Written informed consent for this trial was received from all the
patients. An independent researcher utilized computer-generated
randomization (Microsoft Excel) to determine which procedure the patient
received. All subjects were block-randomized in a 1:1 ratio.
Both groups underwent one session ultrasound-guided HD with 5 mL of
normal saline (NS). Both wrists were allocated to the same group
assuming that participants were diagnosed with bilateral CTS and only
the most symptomatic side was recorded for analysis. Except for
acetaminophen (500 mg, up to 4 g per day), any treatment for CTS was
prohibited for 2 weeks before and 6 months after the injection. A
research assistant performed regular follow-ups on whether additional
therapies were utilized.